Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn’s disease

References

• Chang JT, Longo DL. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020 Dec;383(27):2652–2664. doi: 10.1056/NEJMra2002697
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel J-F, et al. Crohn’s disease. Lancet Lond Engl. 2017 Apr;389(10080):1741–1755. doi: 10.1016/S0140-6736(16)31711-1
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and Perianal Fistulizing Crohn’s disease. Gastroenterology. 2021 Jun;160:(7):2496–2508.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016 Nov;375:(20):1946–1960.
   PubMed Web of Science ®Google Scholar
• Wj S, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013 Aug;369:(8):711–721.
   PubMed Web of Science ®Google Scholar
• Jilani NZ, Akobeng AK, Rutgeerts P. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65. doi: 10.1053/j.gastro.2006.11.041
   PubMed Web of Science ®Google Scholar
• Chinkers M, Garbers DL. The protein kinase domain of the ANP receptor is required for signaling. Science. 1989 Sep;245(4924):1392–1394. doi: 10.1126/science.2571188
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Saharinen P, Pesu M, et al. The janus kinases (Jaks). Genome Biol. 2004;5(12):253. doi: 10.1186/gb-2004-5-12-253
   PubMed Web of Science ®Google Scholar
• Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994 Jun;264(5164):1415–1421. doi: 10.1126/science.8197455
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr;352:(17):1779–1790.
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan;386:(4):316–326.
   PubMed Web of Science ®Google Scholar
• Harris C, Cummings JRF. JAK1 inhibition and inflammatory bowel disease. Rheumatol Oxf Engl. 2021 May;60(Supple 2):ii45–ii51. doi: 10.1093/rheumatology/keaa896
   PubMedGoogle Scholar
• Kohlhuber F, Rogers NC, Watling D, et al. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol Cell Biol. 1997 Feb;17:(2):695–706.
   PubMed Web of Science ®Google Scholar
• Velazquez L, Fellous M, Stark GR, et al. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell. 1992 Jul;70(2):313–322. doi: 10.1016/0092-8674(92)90105-l
   PubMed Web of Science ®Google Scholar
• Ihle JN, Witthuhn BA, Quelle FW, et al. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol. 1995;13(1):369–398. doi: 10.1146/annurev.iy.13.040195.002101
   PubMedGoogle Scholar
• Guschin D, Rogers N, Briscoe J, et al. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. Embo J. 1995 Apr;14:(7):1421–1429.
   PubMed Web of Science ®Google Scholar
• C. for D. E. and Research. FDA approves first oral treatment for moderately to severely active Crohn’s disease. FDA; 2023 May [cited 2023 Sep 3]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-oral-treatment-moderately-severely-active-crohns-disease
   Google Scholar
• EMA. Rinvoq. European Medicines Agency. 2023;26. [Online]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq
   Google Scholar
• Rekić D, Reynolds KS, Zhao P, et al. Clinical drug–drug Interaction Evaluations to Inform drug Use and enable drug access. J Pharm Sci. 2017 Sep;106:(9):2214–2218.
   PubMed Web of Science ®Google Scholar
• Mohamed M-EF, Klünder B, Lacerda AP, et al. Exposure-response analyses for upadacitinib efficacy and safety in the Crohn’s disease CELEST Study and bridging to the Extended-Release Formulation. Clin Pharmacol Ther. 2020;107(3):639–649. doi: 10.1002/cpt.1668
   PubMed Web of Science ®Google Scholar
• Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004 Mar;117(Pt 8):1281–1283. doi: 10.1242/jcs.00963
   PubMed Web of Science ®Google Scholar
• Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatol Oxf Engl. 2019 Jun;58(6):953–962. doi: 10.1093/rheumatology/key339
   PubMed Web of Science ®Google Scholar
• Danese S, Grisham M, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016 Feb;310(3):G155–162. doi: 10.1152/ajpgi.00311.2015
   PubMed Web of Science ®Google Scholar
• Gilardi D, Gabbiadini R, Allocca M, et al. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. Expert Rev Gastroenterol Hepatol. 2020 Sep;14:(9):797–806.
   PubMed Web of Science ®Google Scholar
• Danese S, Argollo M, Le Berre C, et al. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019 Oct;68(10):1893–1899. doi: 10.1136/gutjnl-2019-318448
   PubMed Web of Science ®Google Scholar
• Loftus EV, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for crohn’s disease. N Engl J Med. 2023 May;388(21):1966–1980. doi: 10.1056/NEJMoa2212728
   PubMed Web of Science ®Google Scholar
• Mohamed M-EF, Jungerwirth S, Asatryan A, et al. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. Br J Clin Pharmacol. 2017 Oct;83(10):2242–2248. doi: 10.1111/bcp.13329
   PubMed Web of Science ®Google Scholar
• Mohamed M-EF, Camp HS, Jiang P, et al. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016 Dec;55(12):1547–1558. doi: 10.1007/s40262-016-0419-y
   PubMed Web of Science ®Google Scholar
• Mohamed M-EF, Coppola S, Feng T, et al. Effect of Upadacitinib on the pharmacokinetics of Rosuvastatin or atorvastatin in healthy subjects. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1335–1344. doi: 10.1002/cpdd.957
   PubMed Web of Science ®Google Scholar
• Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007;46(2):133–157. doi: 10.2165/00003088-200746020-00003
   PubMed Web of Science ®Google Scholar
• Mohamed M-EF, Trueman S, Feng T, et al. The JAK1 Inhibitor Upadacitinib Has No Effect on the pharmacokinetics of levonorgestrel and Ethinylestradiol: a study in healthy female subjects. J Clin Pharmacol. 2019 Apr;59(4):510–516. doi: 10.1002/jcph.1350
   PubMed Web of Science ®Google Scholar
• Lefevre PLC, Vande Casteele N. Clinical pharmacology of janus kinase inhibitors in inflammatory bowel disease. J Crohns Colitis. 2020 Aug;14(Supplement_2):S725–S736. doi: 10.1093/ecco-jcc/jjaa014
   PubMed Web of Science ®Google Scholar
• Mohamed M-EF, Klünder B, Othman AA. Clinical pharmacokinetics of Upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet. 2020 May;59(5):531–544. doi: 10.1007/s40262-019-00855-0
   PubMed Web of Science ®Google Scholar
• Mohamed M-EF, Zeng J, Marroum PJ, et al. Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials. Clin Pharmacol Drug Dev. 2019 Feb;8(2):208–216. doi: 10.1002/cpdd.462
   PubMed Web of Science ®Google Scholar
• Hemperly A, Sandborn WJ, Vande Casteele N. Clinical pharmacology in adult and pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2018 Nov;24(12):2527–2542. doi: 10.1093/ibd/izy189
   PubMed Web of Science ®Google Scholar
• Trueman S, Mohamed M-EF, Feng T, et al. Characterization of the effect of hepatic impairment on upadacitinib pharmacokinetics. J Clin Pharmacol. 2019 Sep;59(9):1188–1194. doi: 10.1002/jcph.1414
   PubMed Web of Science ®Google Scholar
• Lea-Henry TN, Carland JE, Stocker SL, et al. Clinical pharmacokinetics in kidney disease. Clin J Am Soc Nephrol CJASN. 2018 Jul;13(7):1085–1095. doi: 10.2215/CJN.00340118
   PubMed Web of Science ®Google Scholar
• Klünder B, Mohamed M-EF, Othman AA. Population pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I and II clinical trials. Clin Pharmacokinet. 2018 Aug;57(8):977–988. doi: 10.1007/s40262-017-0605-6
   PubMed Web of Science ®Google Scholar
• Mohamed M-EF, Trueman S, Feng T, et al. Characterization of the effect of renal impairment on upadacitinib pharmacokinetics. J Clin Pharmacol. 2019 Jun;59(6):856–862. doi: 10.1002/jcph.1375
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Loftus EV, et al. Efficacy and safety of Upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020;158(8):2123–2138.e8. doi: 10.1053/j.gastro.2020.01.047
   PubMed Web of Science ®Google Scholar
• D’Haens G, Panés J, Louis E, et al. Upadacitinib Was Efficacious and well-tolerated over 30 months in patients with Crohn’s disease in the CELEST Extension Study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2022 Oct;20:(10):2337–2346.e3.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021 Mar;80:(3):312–320.
   PubMed Web of Science ®Google Scholar
• Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021 Mar;80:(3):304–311.
   PubMed Web of Science ®Google Scholar
• Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance. Ann Rheum Dis. 2023 Jan;82:(1):119–129.
   PubMed Web of Science ®Google Scholar
• EMA. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. European medicines agency. [cited 2023 Sep 27]. Available from: https://www.ema.europa.eu/en/news/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic
   Google Scholar
• Torres J, Chaparro M, Julsgaard M, et al. European Crohn’s and colitis guidelines on sexuality, fertility, pregnancy, and lactation. J Crohns Colitis. 2023 Jan;17:(1):1–27.
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Feldman SR, Isaacs JD, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf. 2016 Aug;39:(8):755–762.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Dubinsky MC, Su C, et al. Outcomes of pregnancies with Maternal/Paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018 Nov;24:(12):2494–2500.
   PubMed Web of Science ®Google Scholar
• Adam DN, Gooderham MJ, Beecker JR, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol JEADV. 2023 Jun;37:(6):1135–1148.
   PubMed Web of Science ®Google Scholar
• Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013 Nov;38(10):1188–1197. doi: 10.1111/apt.12507
   PubMed Web of Science ®Google Scholar
• Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet Lond Engl. 2019 Apr;393:(10182):1699–1707.
   PubMed Web of Science ®Google Scholar
• D’Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut. 2021 Jul;70(7):1396–1405. doi: 10.1136/gutjnl-2019-320022
   PubMed Web of Science ®Google Scholar
• Ponce-Bobadilla AV, Stodtmann S, Eckert D, et al. Upadacitinib population pharmacokinetics and exposure-response relationships in ulcerative colitis patients. Clin Pharmacokinet. 2023;62(1):101–112. doi: 10.1007/s40262-022-01191-6
   PubMed Web of Science ®Google Scholar
• Muensterman E, Engelhardt B, Gopalakrishnan S, et al. Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – analyses of phase III clinical trials. Clin Transl Sci. 2022 Jan;15(1):267–278. doi: 10.1111/cts.13146
   PubMed Web of Science ®Google Scholar
• Ismail M, Doelger E, Eckert D, et al. Population pharmacokinetic and exposure-response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis. Br J Clin Pharmacol. 2023 Oct;89:(10):3139–3151.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet Lond Engl. 2019 Jun;393:(10188):2303–2311.
   PubMed Web of Science ®Google Scholar
• Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet Lond Engl. 2022 Jun;399:(10341):2113–2128.
   PubMed Web of Science ®Google Scholar
• Marsal J, Barreiro-de Acosta M, Blumenstein I, et al. Management of Non-response and loss of Response to anti-tumor necrosis factor therapy in inflammatory bowel disease. Front Med. 2022 Jun;9:897936. doi: 10.3389/fmed.2022.897936
   Web of Science ®Google Scholar
• Yu B, Zhao L, Jin S, et al. Model-Based Meta-Analysis on the efficacy of biologics and small targeted molecules for Crohn’s disease. Front Immunol. 2022;13:828219. doi: 10.3389/fimmu.2022.828219
   PubMedGoogle Scholar
• Ma C, Battat R, Dulai PS, et al. Innovations in oral therapies for inflammatory bowel disease. Drugs. 2019 Aug;79:(12):1321–1335.
   PubMed Web of Science ®Google Scholar